DE60333866D1 - 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten - Google Patents
2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonistenInfo
- Publication number
- DE60333866D1 DE60333866D1 DE60333866T DE60333866T DE60333866D1 DE 60333866 D1 DE60333866 D1 DE 60333866D1 DE 60333866 T DE60333866 T DE 60333866T DE 60333866 T DE60333866 T DE 60333866T DE 60333866 D1 DE60333866 D1 DE 60333866D1
- Authority
- DE
- Germany
- Prior art keywords
- aminocarbonlyl
- chinoline
- platen
- compounds
- receptor antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 title 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43279202P | 2002-12-11 | 2002-12-11 | |
| PCT/US2003/039079 WO2004052366A1 (en) | 2002-12-11 | 2003-12-09 | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60333866D1 true DE60333866D1 (de) | 2010-09-30 |
Family
ID=32507994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60333866T Expired - Lifetime DE60333866D1 (de) | 2002-12-11 | 2003-12-09 | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7056923B2 (de) |
| EP (1) | EP1578423B1 (de) |
| JP (1) | JP4662777B2 (de) |
| KR (1) | KR20050085580A (de) |
| CN (1) | CN1747732A (de) |
| AP (1) | AP2005003363A0 (de) |
| AT (1) | ATE477800T1 (de) |
| AU (1) | AU2003297763A1 (de) |
| BR (1) | BR0317222A (de) |
| CA (1) | CA2507657C (de) |
| DE (1) | DE60333866D1 (de) |
| EA (1) | EA200500899A1 (de) |
| EC (1) | ECSP055912A (de) |
| ES (1) | ES2348942T3 (de) |
| MX (1) | MXPA05006302A (de) |
| NO (1) | NO20053335L (de) |
| NZ (1) | NZ540872A (de) |
| OA (1) | OA12970A (de) |
| PL (1) | PL377053A1 (de) |
| RS (1) | RS20050450A (de) |
| UA (1) | UA83648C2 (de) |
| WO (1) | WO2004052366A1 (de) |
| ZA (1) | ZA200505492B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040174A1 (en) * | 2003-10-21 | 2005-05-06 | Inspire Pharmaceuticals, Inc. | Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation |
| US7335648B2 (en) * | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2007022241A2 (en) * | 2005-08-17 | 2007-02-22 | Schering Corporation | Novel high affinity quinoline-based kinase ligands |
| DE102006020385A1 (de) * | 2006-04-28 | 2007-10-31 | Dade Behring Marburg Gmbh | Verfahren und Vorrichtung zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen |
| AR063258A1 (es) * | 2006-10-13 | 2009-01-14 | Actelion Pharmaceuticals Ltd | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) * | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| CN101663293B (zh) * | 2007-04-23 | 2013-07-31 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的喹啉-甲酰胺衍生物 |
| JP5371969B2 (ja) | 2007-06-18 | 2013-12-18 | サノフイ | P2y12拮抗薬としてのピロール誘導体 |
| KR101178319B1 (ko) | 2007-11-29 | 2012-09-07 | 액테리온 파마슈티칼 리미티드 | 포스폰산 유도체 및 p2y12 수용체 길항물질로서 이들의 용도 |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| KR101694563B1 (ko) | 2009-04-08 | 2017-01-09 | 액테리온 파마슈티칼 리미티드 | Adp 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘 |
| BRPI1015145A2 (pt) | 2009-04-22 | 2018-01-30 | Actelion Pharmaceuticals Ltd | derivados de tiazol e seu uso como receptores antagonistas de p2y12 |
| CN102304108B (zh) * | 2011-06-28 | 2013-11-06 | 中国药科大学 | 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途 |
| CN104151235B (zh) * | 2014-08-07 | 2016-01-20 | 南阳师范学院 | 一种喹啉衍生物制备方法 |
| PT3515924T (pt) | 2016-09-22 | 2022-03-11 | Idorsia Pharmaceuticals Ltd | Formas cristalinas |
| JP7580918B2 (ja) | 2017-03-15 | 2024-11-12 | イドルシア・ファーマシューティカルズ・リミテッド | P2y12受容体アンタゴニストの皮下投与 |
| CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
| CN112920181A (zh) * | 2021-01-29 | 2021-06-08 | 中国医科大学 | N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US60474A (en) * | 1866-12-18 | Pbtee chick | ||
| GB1334705A (en) | 1970-06-19 | 1973-10-24 | Ici Ltd | Pharmaceutical compositions containing kynurenic acid derivatives |
| US4258192A (en) * | 1977-12-16 | 1981-03-24 | Mitsubishi Chemical Industries Limited | N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof |
| US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
| CA2073776A1 (en) | 1990-11-15 | 1992-05-16 | Joerg Stuerzebecher | Meta-substituted phenyl alanine derivatives |
| CZ245994A3 (en) * | 1993-02-10 | 1995-10-18 | Pentapharm Ag | Piperazides of substituted phenylalanine derivatives as thrombin inhibitors |
| KR0173034B1 (ko) | 1995-04-28 | 1999-03-30 | 성재갑 | 선택적 트롬빈 억제제 |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
-
2003
- 2003-12-09 ES ES03796831T patent/ES2348942T3/es not_active Expired - Lifetime
- 2003-12-09 CN CNA2003801096637A patent/CN1747732A/zh active Pending
- 2003-12-09 BR BR0317222-8A patent/BR0317222A/pt not_active IP Right Cessation
- 2003-12-09 RS YUP-2005/0450A patent/RS20050450A/sr unknown
- 2003-12-09 AT AT03796831T patent/ATE477800T1/de not_active IP Right Cessation
- 2003-12-09 MX MXPA05006302A patent/MXPA05006302A/es active IP Right Grant
- 2003-12-09 JP JP2004558607A patent/JP4662777B2/ja not_active Expired - Fee Related
- 2003-12-09 KR KR1020057010688A patent/KR20050085580A/ko not_active Withdrawn
- 2003-12-09 WO PCT/US2003/039079 patent/WO2004052366A1/en not_active Ceased
- 2003-12-09 AP AP2005003363A patent/AP2005003363A0/xx unknown
- 2003-12-09 CA CA2507657A patent/CA2507657C/en not_active Expired - Fee Related
- 2003-12-09 NZ NZ540872A patent/NZ540872A/en unknown
- 2003-12-09 AU AU2003297763A patent/AU2003297763A1/en not_active Abandoned
- 2003-12-09 US US10/731,815 patent/US7056923B2/en not_active Expired - Fee Related
- 2003-12-09 EP EP03796831A patent/EP1578423B1/de not_active Expired - Lifetime
- 2003-12-09 PL PL377053A patent/PL377053A1/pl not_active Application Discontinuation
- 2003-12-09 EA EA200500899A patent/EA200500899A1/ru unknown
- 2003-12-09 OA OA1200500175A patent/OA12970A/en unknown
- 2003-12-09 DE DE60333866T patent/DE60333866D1/de not_active Expired - Lifetime
- 2003-12-09 UA UAA200506729A patent/UA83648C2/ru unknown
-
2005
- 2005-07-08 NO NO20053335A patent/NO20053335L/no not_active Application Discontinuation
- 2005-07-11 EC EC2005005912A patent/ECSP055912A/es unknown
-
2006
- 2006-01-12 US US11/331,621 patent/US7084142B2/en not_active Expired - Fee Related
- 2006-01-17 ZA ZA200505492A patent/ZA200505492B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS20050450A (sr) | 2007-08-03 |
| KR20050085580A (ko) | 2005-08-29 |
| CA2507657C (en) | 2011-05-31 |
| EP1578423A1 (de) | 2005-09-28 |
| US20060122188A1 (en) | 2006-06-08 |
| JP4662777B2 (ja) | 2011-03-30 |
| PL377053A1 (pl) | 2006-01-23 |
| UA83648C2 (ru) | 2008-08-11 |
| ES2348942T3 (es) | 2010-12-17 |
| NZ540872A (en) | 2007-08-31 |
| CN1747732A (zh) | 2006-03-15 |
| OA12970A (en) | 2006-10-13 |
| NO20053335D0 (no) | 2005-07-08 |
| ZA200505492B (en) | 2006-03-29 |
| US7084142B2 (en) | 2006-08-01 |
| WO2004052366A1 (en) | 2004-06-24 |
| AU2003297763A1 (en) | 2004-06-30 |
| CA2507657A1 (en) | 2004-06-24 |
| BR0317222A (pt) | 2005-11-01 |
| JP2006511519A (ja) | 2006-04-06 |
| NO20053335L (no) | 2005-09-07 |
| AP2005003363A0 (en) | 2005-09-30 |
| ATE477800T1 (de) | 2010-09-15 |
| US20040138229A1 (en) | 2004-07-15 |
| US7056923B2 (en) | 2006-06-06 |
| EP1578423B1 (de) | 2010-08-18 |
| EA200500899A1 (ru) | 2006-02-24 |
| MXPA05006302A (es) | 2005-08-29 |
| WO2004052366A9 (en) | 2005-06-23 |
| ECSP055912A (es) | 2005-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60333866D1 (de) | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten | |
| ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| ATE453647T1 (de) | Adenosin a2a rezeptor antagonisten | |
| ATE293627T1 (de) | Adenosin a2a rezeptor antagonisten | |
| DE60209251D1 (de) | Adenosine a2a receptor antagonisten | |
| CY2016052I1 (el) | Τροποποιημενα φθοριομενα αναλογα νουκλεοζιδιων | |
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| ATE358130T1 (de) | Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten | |
| SMP200600024B (it) | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina | |
| DK1677795T3 (da) | Muskarine acetylcholin-receptor-antagonister | |
| DK1682142T3 (da) | M3-muscarin-acetylcholin-receptor-antagonister | |
| ATE413400T1 (de) | Cgrp-rezeptorantagonisten | |
| IL182528A0 (en) | Purine derivatives for use as adenosin a-2a receptor antagonists | |
| IL175759A0 (en) | A2b adenosine receptor antagonists | |
| BRPI0409787B8 (pt) | antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a | |
| DE60206652D1 (de) | Benzothiazolderivate als adenosin-rezeptor-liganden | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| ATE394402T1 (de) | Kondensierte purinderivate als a1- adenosinrezeptorantagonisten | |
| ATE377008T1 (de) | Imidazolderivate als glutamatrezeptorantagonisten | |
| ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
| DE60305026D1 (de) | 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten | |
| DE60305058D1 (de) | Imidazoquinoline derivate als adenosine a3 rezeptor liganden | |
| DE60214408D1 (de) | 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN | |
| DE602004012555D1 (de) | Benzothiazol-derivate als liganden des adenosinrezeptors | |
| ATE495168T1 (de) | Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten |